Prior studies have suggested that the BET inhibitor JQ1 downregulates the expression of BET-dependent genes. Though JQ1 decreases PDAC tumor growth in animal models, the responses are not durable when it is used as monotherapy. Other studies also have suggested that JQ1 promotes DNA damage by inhibiting DNA repair, causing DNA repair deficiency. Therefore, the investigators hypothesized that the JQ1 would sensitize PDAC tumor cells to the PARP inhibitor olaparib. Read more . . .
The combination of a BET and poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors decreased pancreatic ductal adenocarcinoma (PDAC) growth in preclinical models and may provide a novel approach to treatment, according to a study presented at the 2018 AACR Pancreatic Cancer: Advances in Science and Clinical Care conference in Boston, Massachusetts.